PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma
BackgroundTo develop and validate a new prognostic model using baseline PET parameters and clinical indicators for predicting early overall survival (OS) in Angioimmunoblastic T-cell lymphoma (AITL) patients.MethodsWe conducted a retrospective cohort study from December 2009 to December 2023 (n=124)...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607177/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318469271552000 |
|---|---|
| author | Xiaoxia Xu Xiangxiang Ding Xiao Jin Yunfei Shi Zhi Yang Nan Li |
| author_facet | Xiaoxia Xu Xiangxiang Ding Xiao Jin Yunfei Shi Zhi Yang Nan Li |
| author_sort | Xiaoxia Xu |
| collection | DOAJ |
| description | BackgroundTo develop and validate a new prognostic model using baseline PET parameters and clinical indicators for predicting early overall survival (OS) in Angioimmunoblastic T-cell lymphoma (AITL) patients.MethodsWe conducted a retrospective cohort study from December 2009 to December 2023 (n=124) at a single center. The model’s predictors included baseline clinical characteristics, pathological indicators, laboratory metrics, and PET/CT parameters. Independent prognostic factors were identified using Cox regression and presented as nomograms. The C-index assessed predictive accuracy, while calibration plots and decision curve analysis evaluated prediction accuracy and discrimination ability. The model’s accuracy was compared with existing prognostic systems using C-index, NRI, ROC, and Kaplan-Meier survival curves.ResultsSUVmax, β2MG, platelet, and albumin were identified as independent risk factors. The C-index for OS was 0.78 (95% CI: 0.70-0.85); for 1000 bootstrap samples, it was 0.76 (95% CI: 0.61-0.93). Calibration curves showed excellent agreement between predictions and actual observations. The AUC for 6-month and 1-year OS were 0.91(95% CI: 0.82-1.00) and 0.85 (95% CI: 0.77–0.94), respectively. The model outperformed PIAI, IPI, and PIT in predictive capacity.ConclusionThe new prediction model reliably estimates outcomes for AITL patients, demonstrating high discrimination and calibration. |
| format | Article |
| id | doaj-art-2dc014afccca4c6e88b4151aea5feca9 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2dc014afccca4c6e88b4151aea5feca92025-08-20T03:50:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16071771607177PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphomaXiaoxia Xu0Xiangxiang Ding1Xiao Jin2Yunfei Shi3Zhi Yang4Nan Li5Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, ChinaBackgroundTo develop and validate a new prognostic model using baseline PET parameters and clinical indicators for predicting early overall survival (OS) in Angioimmunoblastic T-cell lymphoma (AITL) patients.MethodsWe conducted a retrospective cohort study from December 2009 to December 2023 (n=124) at a single center. The model’s predictors included baseline clinical characteristics, pathological indicators, laboratory metrics, and PET/CT parameters. Independent prognostic factors were identified using Cox regression and presented as nomograms. The C-index assessed predictive accuracy, while calibration plots and decision curve analysis evaluated prediction accuracy and discrimination ability. The model’s accuracy was compared with existing prognostic systems using C-index, NRI, ROC, and Kaplan-Meier survival curves.ResultsSUVmax, β2MG, platelet, and albumin were identified as independent risk factors. The C-index for OS was 0.78 (95% CI: 0.70-0.85); for 1000 bootstrap samples, it was 0.76 (95% CI: 0.61-0.93). Calibration curves showed excellent agreement between predictions and actual observations. The AUC for 6-month and 1-year OS were 0.91(95% CI: 0.82-1.00) and 0.85 (95% CI: 0.77–0.94), respectively. The model outperformed PIAI, IPI, and PIT in predictive capacity.ConclusionThe new prediction model reliably estimates outcomes for AITL patients, demonstrating high discrimination and calibration.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607177/fullangioimmunoblastic T-cell lymphomaPET/CToverall survivalprediction modelcox regression model |
| spellingShingle | Xiaoxia Xu Xiangxiang Ding Xiao Jin Yunfei Shi Zhi Yang Nan Li PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma Frontiers in Immunology angioimmunoblastic T-cell lymphoma PET/CT overall survival prediction model cox regression model |
| title | PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma |
| title_full | PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma |
| title_fullStr | PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma |
| title_full_unstemmed | PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma |
| title_short | PET/CT-Based prognostic model enhances early survival prediction in angioimmunoblastic t-cell lymphoma |
| title_sort | pet ct based prognostic model enhances early survival prediction in angioimmunoblastic t cell lymphoma |
| topic | angioimmunoblastic T-cell lymphoma PET/CT overall survival prediction model cox regression model |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607177/full |
| work_keys_str_mv | AT xiaoxiaxu petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma AT xiangxiangding petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma AT xiaojin petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma AT yunfeishi petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma AT zhiyang petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma AT nanli petctbasedprognosticmodelenhancesearlysurvivalpredictioninangioimmunoblastictcelllymphoma |